This article is more than 5 years old. Information may no longer be current.

CXCL10, CXCL13 may act as biomarkers for adult-onset Still’s disease

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The chemokines CXCL10 and CXCL13 may be biomarkers associated with adult onset Still’s disease and disease activity, according to recently presented data.

Blood samples were collected from 39 patients with active adult-onset Still’s disease (AOSD) and 40 healthy participants for analysis. Follow-up samples from patients with AOSD were collected about 15 months after the initial tests. Skin biopsies from 26 patients with AOSD presenting skin rashes were also collected.

The levels of both CXCL10 and CXCL13 were higher in patients with AOSD compared with those observed in healthy participants. A correlation between CXCL10 and ferritin and aspartate transaminase levels and systemic scores was also seen. CXCL13 levels correlated with hemoglobin, C-reactive protein, ferritin, albumin and systemic scores. Serum CXCL10 and CXCL13 scores also correlated with each other.

At follow-up, the levels of both CXCL10 and CXCL13 fell significantly, according to the researchers. Skin biopsies of skin exhibiting mucin deposition showed a higher percentage of CXCL10-positive inflammatory cells compared with samples that did not exhibit mucin depositions. Additionally, a positive correlation was seen between the levels of CXCL13 and CD4 and CD68.

“Serum CXCL10 and CXCL13 levels may serve as clinical markers for assessment of disease activity in AOSD,” the researchers wrote. “CXCL10 / CXCR3 and CXCL13 may contribute to the inflammatory response, especially skin manifestations in AOSD.” – by Shirley Pulawski

Reference:

Kim HA, et al. Paper #AB0067. Presented at: European League Against Rheumatism Annual European Congress of Rheumatology; June 10-13, 2015; Rome.

Disclosure: The researchers report no relevant financial disclosures.